Linden Lake Venture Capital

CrossBridge Bio is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes proprietary linker technology and enzymatic conjugation methods to create stable and targeted ADC therapeutics. This approach aims to improve the efficacy and safety profiles of cancer therapies, offering potential advancements in the treatment landscape. By leveraging its unique dual linker payload technology, CrossBridge Bio seeks to revolutionize how cancer is treated, providing new options for patients and healthcare providers.

Vesigen Therapeutics is a biotechnology company focused on developing innovative therapeutic products that address the challenges of targeted intracellular drug delivery. The company's proprietary technology, known as ARMMs (ARRDC1 Mediated Microvesicles), facilitates the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This capability allows for an expanded range of druggable targets and supports the development of new therapies aimed at meeting currently unmet medical needs. By enhancing the delivery mechanisms for next-generation therapeutics, Vesigen Therapeutics aims to contribute significantly to advancements in the field of medicine.